Thangaraju, PSajitha, VSree, Sudha, TYSudheer, DPamidimarri, VNBalasubramanian, VBabu, S2023-08-092023-08-092023-03Thangaraju P, Sajitha V, Sree Sudha TY, Sudheer D, Pamidimarri VN, Balasubramanian V, Babu S. Versatile Use of Mycobacterium indicus pranii (MIP) Vaccine. Indian Journal of Leprosy. 2023 Mar; 95: 51-640254-9395http://imsear.searo.who.int/handle/123456789/222640Mycobacterium indicus pranii (MIP) earlier known as Mw is a soil-borne, non-pathogenic, saprophytic and rapidly growing strain of mycobacteria. MIP is approved as a vaccine/ immunomodulator for various indications including mycobacterium infections like leprosy in humans. Its administration has resulted in satisfactory clinical improvement, accelerated bacillary clearance, and increased immune responses to Mycobacterium leprae antigens, thereby shortening the full recovery time of the patients. It also shares its antigens with M.tuberculosis. In the last decade, RCTs have been done establishing immunotherapeutic properties of MIP in the treatment of leprosy, tuberculosis, warts and experimently in leishmaniasis. Through its immune inducing and cytotoxic property, it has also proved beneficial for human use especially in treating lung cancer. The beneficial role of it is also being explored in breast, cervical, oral, liver, and bladder cancers. Various studies on MIP have shown that it has immune-modulating properties in humans. The curiosity of the human mind has led to it being tried in Covid treatment trials. The results have shown that administering MIP has lowered inflammatory markers in Covid 19 patients, promising us for it to be a potential treatment option. More RCTs with a larger sample size should be done to establish this. Cytokine storm seen in bacterial sepsis is also decreased with MIP administration. Considering the encouraging results in hastening recovery in various diseases it appears that MIP is perhaps not being exploited to its fullest potentialMycobacterium indicus praniiMIPMycobacterium wMwImmunotherapyCovid 19LeprosyTuberculosisImmunomodulatorJournal ArticleIndiaAssistant Professor, Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.Senior Resident, Department of Microbiology, All India Institute of Medical sciences, Raipur, Chhattisgarh, India.Assistant Professor, Department of Pharmacology, All India Institute of Medical Sciences, Deogarh , Jharkhand, India.Department of Industrial Biotechnology, Gujarat Biotechnology University, GD Rd, Sector 11, Gandhinagar, Gujarat 382010, India.Department of Industrial Biotechnology, Gujarat Biotechnology University, GD Rd, Sector 11, Gandhinagar, Gujarat 382010, India.PhD, Amity Institute of Biotechnology, Amity University Chhattisgarh, Raipur 493225, Chhattisgarh, India.Assistant Professor, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India